Cytarabine

Catalog No.S1648

Cytarabine Chemical Structure

Molecular Weight(MW): 243.22

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Size Price Stock Quantity  
USD 97 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Viability and CI vs Fa after 24-h exposure to cytarabine alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM (500 ng/ml for cytarabine; quadruplicates±s.e.m.).

    Leukemia, 2015, 29(8): 1702–1712. Cytarabine purchased from Selleck.

    Cell cycle was analyzed using propidium iodide (PI) staining and flow cytometry. The plots show PI staining at the x-axis and cell counts at the y-axis. The graphs were prepared using ModFit LT™ software (Verity Software House). Nd: not detected, Ara-c:Cytarabine

    J Exp Clin Cancer Res, 2017, 36(1):22. Cytarabine purchased from Selleck.

  • Flow cytometry analysis for cell surface expression of CD11b shows time- and dose-dependent upregulation of the marker CD11b in MLL-rearranged leukemia cells treated with EPZ-5676 and Cytarabine(Ara-C) as single agents and in combination.

    J Pharmacol Exp Ther, 2014, 350(3): 646-56. Cytarabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.
Features The 1st of a series of cancer drugs that alters the sugar component of nucleosides.
Targets
DNA synthesis [1]
(CCRF-CEM cells)
16 nM
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. [1] Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. [2] Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse L1210 cells NGqwOJVEgXSxdH;4bYPDqGG|c3H5 MlixN{Bl[Xm| NXK4N|N4S3m2b4TvfIlkcXS7IHHnZYlve3RiZHXvfJlvfWOuZX;zbYRmKGGwYXzv[5VmNXOnboPpeIl3\SCvb4Xz[UBNOTJzMDDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvPCCwTT6= MV[xPVY4PDlyMx?=
human CCRF-CEM cells MmO5R5l1d3SxeHnjxsBie3OjeR?= M4HxVFMh\GG7cx?= MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBl\W:6eX71Z4xmd3OrZHWgZY5idG:pdXWtd4Vve2m2aY\lJIh2dWGwIFPDVmYuS0WPIHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NUBvVS5? Ml7JNVk3PzR7MEO=
human MCF7 cells NVLvbIlkS3m2b4TvfIlkyqCjc4PhfS=> MlfzN{Bl[Xm| MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBl\W:6eX71Z4xmd3OrZHWgZY5idG:pdXWtd4Vve2m2aY\lJIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiMzDkZZl{KGK7IF3UWEBie3OjeTygTWM2OD12IH7NMi=> NGT1doYyQTZ5NEmwNy=>
CCRF-CEM cell line MVnGeY5kfGmxbjDhd5NigQ>? NGnG[3JKdmirYnn0JJRp\SC{ZYDsbYNifGmxbjDv[kBES1KILVPFUUBk\WyuIHzpcoUhcW5idnn0do8tKEWGNUC9OUBvVS5? MU[xPVk2QDl2
human P12-ICHIKAWA cell M133RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEH2[ZFKdmirYnn0bY9vKG:oIHj1cYFvKFBzMj3JR2hKU0GZQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOVQhdk1w Mn7LV2FPT0WU
human CCRF-CEM cells NGP1fItEgXSxdH;4bYPDqGG|c3H5 NXn0XlgyPDhiaB?= NVT0XIh7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0OURj3DSW0h[2WubIOgZYZ1\XJiNEigbJJ{KGK7IHPlcIwhfGm2ZYKtZox2\SCjc4PhfUwhTUN3ME21MlYyKG6PLh?= MX[xPVc1Ozh3OB?=
CCRF-CEM cell lines MXnGeY5kfGmxbjDhd5NigQ>? NUi2[mR[PzJiaB?= M324NmNwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDDy[ZBtcWOjdHnvckBw\iCFQ2LGMWNGVSClZXzsJIxqdmW|IHL5JFUxLSCjZoTldkA4OiCqcjDpcoN2[mG2aX;uMEBGTDVyPU[gcm0v MWqxOlUzODJ2
human CCRF-CEM cells NWrpSXhOS3m2b4TvfIlkyqCjc4PhfS=> MYe0PEBp NYX5V4JCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0OURj3DSW0h[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IHPlcIx1cXSncj3icJVmKGG|c3H5MEBKSzVyPU[gcm0v M1vm[VIzPTh{OUmx
human SF268 cells Mn;QR5l1d3SxeHnjxsBie3OjeR?= NF;mWIhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ4ODDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;Nz62PEBvVS5? MYqxPVM1PTV6MR?=
MOLT-4 human leukemic lymphoblastoid cell lines NGfObVBEgXSxdH;4bYPDqGG|c3H5 MlXLR5l1d3SxeHnjbZR6KGGpYXnud5QhVU:OVD20JIh2dWGwIHzleYtmdWmlIHz5cZBpd2KuYYP0c4llKGOnbHygcIlv\XNuIFnDOVA:OTBibl2u NWfqPY81Pjh{N{W0Oi=>
human 697 cell NIi3codIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEO1SZhKdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlYhdk1w NHzsR3dUSU6JRWK=
human ES1 cell M{WycGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{DidGlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKuPVchdk1w M4q5W3NCVkeHUh?=
CCRF-CEM human leukemic lymphoblastoid cell lines Mme4R5l1d3SxeHnjxsBie3OjeR?= NVzIOHVrS3m2b4TvfIlkcXS7IHHnZYlve3RiQ1PSSk1ETU1iaIXtZY4hdGW3a3XtbYMhdHmvcHjvZoxie3SxaXSgZ4VtdCCuaX7ld{whUUN3ME2yNEBvVS5? M1jmTlY5Ojd3NE[=
P388 murine cell lines NGLUNYxHfW6ldHnvckBie3OjeR?= Mne4O|IhcA>? Mlf0WIhmKGOxbYDveY5lKHejczD0[ZN1\WRiaX6geol1em9iZn;yJIFvfGm2dX3vdkBi[3Srdnn0fUg2OCViaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEkh[WejaX7zeEB1cGViUEO4PEBufXKrbnWgZ4VtdCCuaX7ld{Bi\nSncjC3NkBpd3W{czygTWQ2OD1{MDDuUU4> MkXvN|YzPTdzNB?=
L1210 murine cell lines NWXZcFl[TnWwY4Tpc44h[XO|YYm= M2DZW|czKGh? MlfqWIhmKGOxbYDveY5lKHejczD0[ZN1\WRiaX6geol1em9iZn;yJIFvfGm2dX3vdkBi[3Srdnn0fUg2OCViaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEkh[WejaX7zeEB1cGViTEGyNVAhdXW{aX7lJINmdGxibHnu[ZMh[W[2ZYKgO|IhcG:3coOsJGlFPTB;MkCgcm0v MV2zOlI2PzF2
human HEL cell M3v3TGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJyLkWyJI5ONg>? NYHS[3JLW0GQR1XS
human CCRF-CEM/C2 cells MX;DfZRwfG:6aXRCpIF{e2G7 M364RlQ5KGh? MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDR3JHNUOHTT;DNkBk\WyuczDh[pRmeiB2ODDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBGSzVyPUKyMlghdk1w MV[xPVc1Ozh3OB?=
mouse L1210 cells MlvmR5l1d3SxeHnjxsBie3OjeR?= MoXoOFghcA>? M2fFSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGwyOjFyIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFQ5KGi{czygTWM2OD1yLkCyOEDPxE1w NYrHW3M3OjByMEC0NVg>
human CEM cells NGnBdXdEgXSxdH;4bYPDqGG|c3H5 NWmxUHlwPDhiaB?= M13V[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC0PEBpenNuIFnDOVA:OC5yMkSg{txONg>? Mk\1NlAxODB2MUi=
human 2209-23 cells MWrQdo9tcW[ncnH0bY9vKGG|c3H5 NUfTNpJzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjCyNlA6NTJ|IHPlcIx{KGK7IGuzTH11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDzZ4lvfGmubHH0bY9vKHC{b4jpcYl1gSCjc4PhfUwhUUN3ME2wMlAzQSEQvF2= NETv[JUyQTB3NUS4Ni=>
human CHP-212 cell NWS3fmNwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGLXUYxKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Oy52NzDuUU4> M{iyOHNCVkeHUh?=
human CTB-1 cell M2LoOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJGNVSi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{SuN{BvVQ>? MknXV2FPT0WU
human A427 cell MnLTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUe4UIJIUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|QvPDlibl2u MUXTRW5ITVJ?
human MOLT-16 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVfJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOk4xPyCwTT6= M1v6fHNCVkeHUh?=
human MCF7 1K cells MUnDfZRwfG:6aXRCpIF{e2G7 MYmzJIRigXN? NGO1[YFEgXSxdH;4bYNqfHliYXfhbY5{fCCmZX;4fY52[2ynb4Pp[IUh[W6jbH;neYUuemW|aYP0ZY51KGi3bXHuJG1ETjdiMVugZ4VtdHNib4\ldoV5eHKnc4Ppcochemmkb371Z4xmd3SrZHWgdoVlfWO2YYPlJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;NECgcm0v Ml7DNVk3PzR7MEO=
human MC-IXC cell NELLO2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoTDTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20NU41OSCwTT6= NH3pWnJUSU6JRWK=
human BHT-101 cell M1rpUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVHmOItQUW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDFwN{[gcm0> NFrQUm1USU6JRWK=
human K5 cell NFfydmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDNwMjDuUS=> MUfTRW5ITVJ?
parent promyelocytic leukemia cell line MWDGeY5kfGmxbjDhd5NigQ>? M2TjUGFvfGmlYX7j[ZIh[WO2aY\peJkhf2G|IHX2ZYx2[XSnZDDmc5IhfGinIHPvcZBwfW6mIHHnZYlve3RicHHy[Y51KHC{b335[Yxw[3m2aXOgcIV2c2WvaXGgZ4VtdCCuaX7lJEhJVC14MD3HTHBTXCtxZFPLL{ktKEWGNUC9OFchdk1w NVXUZnVnOzB{N{OyPS=>
human HL60 cells MWXDfZRwfG:6aXRCpIF{e2G7 MkDBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgZ4VtdHSrdHXyMYJtfWViYYPzZZktKEmFNUC9NE4xPDlizszNMi=> MUKyNlU5Ojl7MR?=
human A549 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12OT62OkBvVQ>? NHnyXZVUSU6JRWK=
human NCI-H1703 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEfrV2JKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVcxOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR7LkixJI5O NVv4cFNbW0GQR1XS
L1210 cell lines MVrGeY5kfGmxbjDhd5NigQ>? MkjUR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IILldIxq[2G2aX;uJI9nKExzMkGwJINmdGxibHnu[ZMh[nliNUClJIFnfGW{IEeyJIhzKGmwY4XiZZRqd25uIFXEOVA:OC5yNTFOwG0v NU\kWZYyOTZ3MkCyOC=>
human K562 cells Moi3R5l1d3SxeHnjxsBie3OjeR?= NWSxSoZFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6wOUDPxE1? M1TwdVI1QTV4NUW2
human LB2241-RCC cell NGe5ZnJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkfFTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTVwM{Sgcm0> NYTGZlZZW0GQR1XS
human MLMA cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXqyfZNwUW6qaXLpeIlwdiCxZjDoeY1idiCPTF3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVUvPTFibl2= NHHDNWJUSU6JRWK=
human P30-OHK cell NYXLclVRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkmwTY5pcWKrdHnvckBw\iCqdX3hckBROzBvT1jLJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVYvPSCwTR?= M3TkUXNCVkeHUh?=
RPMI-6410 human leukemic lymphoblastoid cell lines M2fObGN6fG:2b4jpZ:Kh[XO|YYm= NXm2T25wS3m2b4TvfIlkcXS7IHHnZYlve3RiUmDNTU03PDFyIHj1cYFvKGyndXvlcYlkKGy7bYDoc4Jt[XO2b3nkJINmdGxibHnu[ZMtKEmFNUC9NE4xPiEQvF2= M3ywbFY5Ojd3NE[=
human HT-29 cells NY\TenVLWHKxbHnm[ZJifGmxbjDhd5NigQ>? Mm\wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwME[2JO69VS5? MkDNNlc4QDR2OR?=
human NCI-H510A cell M{\NcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPEOnFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVExSSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ6LkK2JI5O MnHtV2FPT0WU
human J-RT3-T3-5 cell MlfSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M17zVmlvcGmkaYTpc44hd2ZiaIXtZY4hUi2UVEOtWFMuPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ6LkSyJI5O NV7ZcZB{W0GQR1XS
human VA-ES-BJ cell NVPBc2tnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2DJ[WlvcGmkaYTpc44hd2ZiaIXtZY4hXkFvRWOtRmoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04OS54NTDuUS=> MVfTRW5ITVJ?
human T-24 cell NHj3[3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3vVOGlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe4MlU3KG6P NYHRU41QW0GQR1XS
human NB69 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHPHN4lKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23PU41QCCwTR?= MoDNV2FPT0WU
human BALL-1 cells NVv0TXV7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWPNNYtiOjRiaB?= MonIS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRmFNVC1zIHPlcIx{KGGodHXyJFI1KGi{czDifUBYW1RvMTDhd5NigSxiR1m1NF0xNjB6IN88US=> MXSyNlI3PDF5MB?=
HL60 cells NVzCWYVnWHKxbHnm[ZJifGmxbjDhd5NigQ>? NF;jXpdKdiC4aYTyc{BqdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDwdo9tcW[ncnH0bY9vKG:oIFjMOlAh[2WubIOsJGlEPTB;MD6wPEDPxE1? MYWxNlg4PzV7Mx?=
human CTV-1 cell M3fzUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFPkXFNKdmirYnn0bY9vKG:oIHj1cYFvKEOWVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFQvPzRibl2= NUnUUnJLW0GQR1XS
human MEL-JUSO cell MnHOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFLFTXdKdmirYnn0bY9vKG:oIHj1cYFvKE2HTD3KWXNQKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QDVwN{[gcm0> M4Hze3NCVkeHUh?=
human MOLT-4 cell MlflS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHn5VG9KdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg6NjZ5IH7N MVLTRW5ITVJ?
human leukemia cell line(CCRF-CEM) NFjHTnhEgXSxdH;4bYPDqGG|c3H5 NVfwbFJbUW5idnn0do8h[3m2b4TvfIlkcXS7IH;mJINwdXCxdX7kd{B4\XKnIHTleIVzdWmwZXSgc44hUW6qaXLpeIlwdiCxZjDoeY1idiCuZYXr[Y1q[SClZXzsJIxqdmVqQ1PSSk1ETU1rLDDJR|UxRTBwMEmg{txONg>? NHqzOJU5QTF5NkS1
human SW982 cell NXrLbIxCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnzTTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmxMlI{KG6P MmruV2FPT0WU
human NCI-SNU-1 cell NW\pTG9qT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NELqNlJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G778{MJGlEPTB;OU[uO|chdk1? M3\HWXNCVkeHUh?=
HeLa human cell lines MXfGeY5kfGmxbjDhd5NigQ>? NVS4e2NuOTR2IHi= M1vkU3Rp\SClb33wc5Vv\CC5YYOgeIV{fGWmIHnuJJZqfHKxIH\vdkBidnSrdIXtc5Ih[WO2aY\peJkpPTBnIHnubIljcXSrb36gc4YhfHWvb4KgZ4VtdCCpcn;3eIgqKGGpYXnud5QhUGWOYTDoeY1idiClZXzsJIxqdmW|IHHmeIVzKDF2NDDodkwhUUR3ME2wMlEh|ryP NWXsbmlvOzZ{NUexOC=>
human H460 cells M2O5WWZ2dmO2aX;uJIF{e2G7 MYiyOEBp MnfCRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7wrC= NWPXfHJKOjB{MUG1OlQ>
human HCT116 cells M3u0fWZ2dmO2aX;uJIF{e2G7 Mn3aRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xJO69VQ>? MWCyNFIyOTV4NB?=
human GP5d cell M3;jdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVq3dXNiUW6qaXLpeIlwdiCxZjDoeY1idiCJUEXkJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAzKG6P NXvGfXBbW0GQR1XS
human SAS cell NU[yb4xDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlryTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEeuOVchdk1? MlLqV2FPT0WU
human BFTC-905 cell  M2T6cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYDUb4lsUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyOD6zNUBvVQ>? NX7Sb2ZWW0GQR1XS
human LB1047-RCC cell NET6XXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFzqV4FKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEiuOFIhdk1? NWXyXmlrW0GQR1XS
human BB65-RCC cell M{TOUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4T5[WlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ4NT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOTBwMUmgcm0> M3jEbnNCVkeHUh?=
human KE-37 cell Mn[wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGtGNTN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGwMlg2KG6P MXnTRW5ITVJ?
human NCI-H292 cell M1HoZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV7ZSmE{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzND6yJI5O Ml7GV2FPT0WU
human HT-1080 cell NUDHT2FuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNVQvPDdibl2= M{PVUXNCVkeHUh?=
human HL60 cells NEmzVYlEgXSxdH;4bYPDqGG|c3H5 M3zFZ|Q5KGh? NVqwOpR1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOTF6IN88US=> NVjhNYNbOTl|MkGyN|Q>
human CAKI-1 cell M2DjNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUHDeXRwT3Kxd4ToJIlvcGmkaYTpc44hd2ZiYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KFeVVD2xJIF{e2G7LDDHTVUxRTBwMUKg{txO NHHyXHczOjJ4NEG3NC=>
human CAKI-1 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmOxTY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlAhdk1? MU\TRW5ITVJ?
human HMV-II cell M2jje2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1[4bGlvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZk> MkLSV2FPT0WU
human ES8 cell NIjCOHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlT5TY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMkOuPVMhdk1? MojKV2FPT0WU
human NEC8 cell M{TzU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml3KTY5pcWKrdHnvckBw\iCqdX3hckBPTUN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUO0MlIyKG6P NFfLO2RUSU6JRWK=
human EW-1 cell NGDZW2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVnJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zM{iuOlIhdk1? NGToe4xUSU6JRWK=
murine leukemia P388 NUHWVHpRTnWwY4Tpc44h[XO|YYm= NH7jTnZCdnSrY3HuZ4VzKGGldHn2bZR6KGOjcoLp[YQhd3W2IHnuJJZqfHKxIHHnZYlve3RibYXybY5mKGyndXvlcYliKFB|OEisJGlEPTB;MD6xOEDPxE1? M4XOS|EyOzV4MUGw
human H-EMC-SS cell MlHwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXjqcGRPUW6qaXLpeIlwdiCxZjDoeY1idiCKLVXNR{1UWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF2NT6yPEBvVQ>? M2LZVHNCVkeHUh?=
human SNU638 cells NHvwe29EgXSxdH;4bYPDqGG|c3H5 M1\EZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPXTZ|ODDj[YxteyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6xOUDPxE1? M1LlUVI1QTV4NUW2
human COR-L105 cell M{jC[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYxNjN7IH7N MVfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. [4] Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity. [5]

Protocol

Kinase Assay:[1]
+ Expand

In Vitro Growth Inhibition Assay:

Stock solution of Cytarabine is prepared in absolute ethanol, and serial dilutions of Cytarabine are prepared. CCRF-CEM cells are suspended in RPMI medium supplemented with 10% FBS, 0.1% gentamicin, and 1% sodium pyruvate. The cells are suspended in their respective media to give 10 mL volumes of cell suspension at a final density of 3-6 × 104 cells/mL. Appropriate volumes of Cytarabine solution are transferred to the cell suspensions, and incubation is continued for 72 hours. The cells are spun down and resuspended in fresh Cytarabine -free medium, and final cell counts are determined. The data are analyzed by sigmoidal curve fitting of the cell count versus Cytarabine concentration, and the results are expressed as the IC50 (Cytarabine concentration that inhibits cell growth to 50% of the control value).
Cell Research:[2]
+ Expand
  • Cell lines: Rat leukemic cell lines RCL/0, RO/1 and K7 and human myelomonocytic leukemic U937
  • Concentrations: ~100 μM
  • Incubation Time: 24, 48 and 72 hours
  • Method: Cells are incubated in the presence of different concentrations of Cytarabine at 37 °C for 24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4-hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Brown Norway rat with myelocytic leukaemia
  • Formulation: Dissolved in phosphate-buffered saline (pH 7.0) just before use.
  • Dosages: 5 - 1000 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro Water 48 mg/mL (197.35 mM)
DMSO 1 mg/mL (4.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 243.22
Formula

C9H13N3O5

CAS No. 147-94-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756962 Recruiting Acute Myeloid Leukemia Washington University School of Medicine July 6, 2016 Phase 2
NCT01555268 Completed Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia Roswell Park Cancer Institute|National Cancer Institute (NCI)|Amgen October 31, 2011 Phase 1
NCT02203526 Suspended Primary Central Nervious System Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 24, 2014 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT02483000 Not yet recruiting Adult Burkitt Lymphoma|Adult Diffuse Large B-Cell Lymphoma|CD20-Positive Neoplastic Cells Present|Indolent Adult Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory Mature B-Cell Non-Hodgkin Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) March 2017 Phase 1
NCT03019640 Not yet recruiting B-Cell Non-Hodgkin Lymphoma M.D. Anderson Cancer Center March 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Cytarabine | Cytarabine supplier | purchase Cytarabine | Cytarabine cost | Cytarabine manufacturer | order Cytarabine | Cytarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID